T1-2N1M0 nasopharyngeal carcinoma chemotherapy or not: A retrospective study
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0279252 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Pei-Jing Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy & Oncology, The Second Affiliated Hospital of Soochow University, Institute of Radiotherapy & Oncology, Soochow University…. Hauptthemen laut MEDLINE: Radiation Oncology, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Medical Innovation Team, Suzhou Science and Technology Development Program.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Radiotherapy (RT) combined with chemotherapy is the standard treatment for T 1-2 N 1 M 0 nasopharyngeal carcinoma (NPC) based on conventional radiotherapy. However, intensity-modulated radiotherapy (IMRT) has narrowed the treatment gap between RT and chemoradiotherapy. Thus, this retrospective study aimed to compare the efficacy of RT and chemoradiotherapy (RT-chemo) in treating T 1-2 N 1 M 0 NPC in the IMRT era. Materials and methods From January 2008 to December 2016, 343 consecutive patients with T 1-2 N 1 M 0 NPC in two cancer centers were included. All patients received RT or RT-chemo, chemotherapy including induction chemotherapy (IC) + concurrent chemoradiotherapy (CCRT), CCRT, or CCRT + adjuvant chemotherapy (AC). The number of patients who received RT, CCRT, IC + CCRT, and CCRT + AC was 114, 101, 89, and 39. The survival rates were analyzed using the Kaplan-Meier method and compared using the log-rank test. Multivariable analysis was performed to identify valuable prognostic factors.
Results
The median follow-up time for survivors was 93 (range: 55–144) months. The 5-year overall survival (OS), progression-free survival (PFS), locoregional failure-free survival (LRFFS), and distant metastasis-free survival (DMFS) for the RT-chemo and RT groups were 93.7%, 88.5%, 93.8%, 93.8% and 93.0%, 87.7%, 91.9%, 91.2%, respectively (P>0.05 for all outcomes). No significant survival differences were found between the two groups. The T 1 N 1 M 0 or T 2 N 1 M 0 subgroup analysis showed that treatment outcomes had no significant differences between the RT and RT-chemo groups. After adjusting for various factors, treatment mode was not identified as an independent prognostic factor for all survival rates.
Conclusions
In this study, outcomes of T 1-2 N 1 M 0 NPC patients treated by IMRT alone were comparable to chemoradiotherapy, supporting the omission or postponement of chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiotherapy & Oncology, The Second Affiliated Hospital of Soochow University, Institute of Radiotherapy & Oncology, Soochow University, Suzhou Key Laboratory for Radiation Oncology, Suzhou, China.
- Department of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
- Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
ORCID-Profile: Pei-Jing Li, Ye Tian
Förderung
- Jiangsu Medical Innovation Team
- Suzhou Science and Technology Development Program
Zitieren
APA
Li, P. J., Chen, M., & Tian, Y. (2023). T1-2N1M0 nasopharyngeal carcinoma chemotherapy or not: A retrospective study. PLOS ONE. https://doi.org/10.1371/journal.pone.0279252
Vancouver
Li PJ, Chen M, Tian Y. T1-2N1M0 nasopharyngeal carcinoma chemotherapy or not: A retrospective study. PLOS ONE. 2023. doi:10.1371/journal.pone.0279252
BibTeX
@article{Li2023,
author = {Li, Pei-Jing and Chen, Ming and Tian, Ye},
title = {T1-2N1M0 nasopharyngeal carcinoma chemotherapy or not: A retrospective study},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0279252}
}
EUVIMED